{"id":"dexchlorpheniramine","rwe":[{"pmid":"30000848","year":"2006","title":"Dexchlorpheniramine.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39740223","year":"2025","title":"Fixed Drug Eruption due to Chlorpheniramine: Case Report.","finding":"","journal":"Contact dermatitis","studyType":"Clinical Study"},{"pmid":"39265704","year":"2024","title":"Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial.","finding":"","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","studyType":"Clinical Study"},{"pmid":"38646551","year":"2024","title":"Efficacy and safety of different systemic drugs in the treatment of uremic pruritus among hemodialysis patients: a network meta-analysis based on randomized clinical trials.","finding":"","journal":"Frontiers in medicine","studyType":"Clinical Study"},{"pmid":"38239332","year":"2024","title":"Successful discontinuation of corticosteroids through remission induction therapy with benralizumab for chronic eosinophilic pneumonia.","finding":"","journal":"Respirology case reports","studyType":"Clinical Study"}],"_fda":{"id":"47e37a4b-be9d-3c99-e063-6394a90ac7c7","set_id":"0c7c6756-abb2-c10c-e063-6394a90a9863","openfda":{"upc":["0358809190164"],"unii":["69QQ58998Y","B10YD955QW"],"route":["ORAL"],"rxcui":["2671454"],"spl_id":["47e37a4b-be9d-3c99-e063-6394a90ac7c7"],"brand_name":["VanaCof 2"],"spl_set_id":["0c7c6756-abb2-c10c-e063-6394a90a9863"],"package_ndc":["58809-190-16"],"product_ndc":["58809-190"],"generic_name":["CHLOPHEDIANOL HCL, DEXCHLORPHENIRAMINE MALEATE"],"product_type":["HUMAN OTC DRUG"],"substance_name":["CHLOPHEDIANOL HYDROCHLORIDE","DEXCHLORPHENIRAMINE MALEATE"],"manufacturer_name":["GM Pharmaceuticals, INC"],"application_number":["M012"],"is_original_packager":[true]},"purpose":["Purpose Cough Suppressant Antihistamine"],"version":"5","stop_use":["Stop use and ask a doctor if ■ cough persists for more than 1 week, tends to recur, or is accompanied by a fever, rash or persistent headache. A persistent cough may be a sign of a serious condition. ■ new symptoms occur"],"warnings":["Warnings Ask a doctor before use if you have ■ a cough that lasts or is chronic such as occurs with smoking, asthma, or emphysema ■ a cough that occurs with too much phlegm (mucus) ■ a breathing problem such as emphysema or chronic bronchitis ■ trouble urinating due to an enlarged prostate gland ■ glaucoma Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers When using this product ■ excitability may occur, especially in children ■ may cause marked drowsiness ■ alcohol, sedatives, and tranquilizers may increase the drowsiness effect ■ avoid alcoholic drinks ■ use caution when driving a motor vehicle or operating machinery Stop use and ask a doctor if ■ cough persists for more than 1 week, tends to recur, or is accompanied by a fever, rash or persistent headache. A persistent cough may be a sign of a serious condition. ■ new symptoms occur If pregnant or breast-feeding, ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"questions":["Questions? Call 1-888-535-0305 9a.m. - 5p.m. CST"],"ask_doctor":["Ask a doctor before use if you have ■ a cough that lasts or is chronic such as occurs with smoking, asthma, or emphysema ■ a cough that occurs with too much phlegm (mucus) ■ a breathing problem such as emphysema or chronic bronchitis ■ trouble urinating due to an enlarged prostate gland ■ glaucoma"],"when_using":["When using this product ■ excitability may occur, especially in children ■ may cause marked drowsiness ■ alcohol, sedatives, and tranquilizers may increase the drowsiness effect ■ avoid alcoholic drinks ■ use caution when driving a motor vehicle or operating machinery"],"effective_time":"20260108","active_ingredient":["Active ingredients in each 5 mL (1 teaspoonful) Chlophedianol HCI 12.5 mg Dexchlorpheniramine Maleate 1 mg"],"inactive_ingredient":["Inactive ingredients citric acid anhydrous, flavor, glycerin, propylene glycol, purified water, sodium benzoate, sodium citrate dihydrate, sorbitol solution, sucralose"],"storage_and_handling":["Other information ■ this packaging is child-resistant. ■ store at room temperature of 68°-86°F (20°-30°C) with excursions of 59°-86°F (15°-30°C)"],"indications_and_usage":["Uses ■ temporarily relieves these symptoms due to the common cold, hay fever (allergic rhinitis) or other upper respiratory allergies: ■ runny nose ■ sneezing ■ itching of the nose or throat ■ itchy, watery eyes ■ cough due to minor throat and bronchial irritation"],"ask_doctor_or_pharmacist":["Ask a doctor or pharmacist before use if you are taking sedatives or tranquilizers"],"spl_unclassified_section":["Distributed by: GM Pharmaceuticals, Inc. Fort Worth, TX 76118"],"dosage_and_administration":["Directions do not exceed recommended dosage. adults and children 12 years of age and over: 2 teaspoonfuls (10 mL) every 6 hours, not to exceed 8 teaspoonfuls (40 mL) in 24 hours. children 6 to under 12 years of age: 1 teaspoonful (5 mL) every 6 hours, not to exceed 4 teaspoonfuls (20 mL) in 24 hours. children under 6 years of age: consult a doctor."],"spl_product_data_elements":["VanaCof 2 Chlophedianol HCl, Dexchlorpheniramine Maleate WATER PROPYLENE GLYCOL SODIUM BENZOATE SORBITOL SOLUTION DEXCHLORPHENIRAMINE MALEATE DEXCHLORPHENIRAMINE CHLOPHEDIANOL HYDROCHLORIDE CHLOPHEDIANOL ANHYDROUS CITRIC ACID SUCRALOSE GLYCERIN TRISODIUM CITRATE DIHYDRATE"],"pregnancy_or_breast_feeding":["If pregnant or breast-feeding, ask a health professional before use."],"keep_out_of_reach_of_children":["Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away."],"dosage_and_administration_table":["<table border=\"1\" cellpadding=\"1\" cellspacing=\"1\" width=\"100%\"><tbody><tr><td>adults and children 12 years of age and over:</td><td><paragraph>2 teaspoonfuls (10 mL) every 6 hours, not to exceed 8 teaspoonfuls   (40 mL) in 24 hours. </paragraph></td></tr><tr><td>children 6 to under 12 years of age:</td><td><paragraph>1 teaspoonful (5 mL) every 6 hours, not to exceed 4 teaspoonfuls   (20 mL) in 24 hours. </paragraph></td></tr><tr><td>children under 6 years of age:</td><td>consult a doctor.</td></tr></tbody></table>"],"package_label_principal_display_panel":["NDC 58809-190-16 VanaCof® 2 EACH 5 mL (1 TEASPOONFUL) CONTAINS: Chlophedianol HCI..........................12.5 mg Dexchlorpheniramine Maleate............1 mg Cough Suppressant Antihistamine Sugar Free, Alcohol Free, Dye Free Tamper evident by foil seal under cap. Do not use if foil seal is broken or missing. THIS BOTTLE IS NOT TO BE DISPENSED TO CONSUMER. Dispense in a tight, light-resistant container with a child-resistant cap. US Patent # 9,463,191 US Patent # 9,050,289 GM Pharmaceuticals, Inc. 16 fl. oz. (473 mL) VanaCof 2 Label"]},"tags":[{"label":"dexchlorpheniramine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histamine H1 receptor","category":"target"},{"label":"HRH1","category":"gene"},{"label":"SLC6A4","category":"gene"},{"label":"CHRM4","category":"gene"},{"label":"R06AB02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Liquid","category":"form"},{"label":"Solution","category":"form"},{"label":"Syrup","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Allergic conjunctivitis","category":"indication"},{"label":"Allergic rhinitis","category":"indication"},{"label":"Dermatographic urticaria","category":"indication"},{"label":"Itching of skin","category":"indication"},{"label":"Seasonal allergic rhinitis","category":"indication"},{"label":"Urticaria","category":"indication"},{"label":"Approved 1980s","category":"decade"},{"label":"Histamine Agents","category":"pharmacology"},{"label":"Histamine Antagonists","category":"pharmacology"},{"label":"Histamine H1 Antagonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"75 reports"},{"date":"","signal":"INFUSION RELATED REACTION","source":"FDA FAERS","actionTaken":"64 reports"},{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"58 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"51 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"49 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"49 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"46 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"45 reports"},{"date":"","signal":"MALAISE","source":"FDA FAERS","actionTaken":"41 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"40 reports"}],"commonSideEffects":[],"contraindications":["Achalasia of esophagus","Acidosis","Acute abdominal pain","Acute exacerbation of asthma","Acute hepatitis","Acute pancreatitis","Alcohol intoxication","Alcohol withdrawal delirium","Alcoholism","Angle-closure glaucoma","Arterial thrombosis","Arteriosclerotic vascular disease","Asthenia","Atony of colon","Autonomic dysreflexia","Benign intracranial hypertension","Benign prostatic hyperplasia","Bladder outflow obstruction","Bleeding","Bradycardia","Brain damage","Breastfeeding (mother)","Central nervous system depression","Chronic disease of respiratory system","Chronic heart failure"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DEXCHLORPHENIRAMINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:39:09.217279+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:39:17.234971+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:39:08.338071+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXCHLORPHENIRAMINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:39:17.650112+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:39:07.889293+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:39:07.889317+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:39:19.120536+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:39:18.704063+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200927/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:39:18.364031+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"M012","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:39:07.889320+00:00"}},"allNames":"dexchlorpheniramine maleate","offLabel":[],"synonyms":["dexchlorpheniramine","(+)-Chloropheniramine","(+)-Chlorpheniramine","S-Chlorpheniramine","d-Chlorpheniramine","dexchlorpheniramine maleate"],"timeline":[{"date":"1981-07-14","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"aiSummary":"Dexchlorpheniramine Maleate (DEXCHLORPHENIRAMINE) is a small molecule drug that targets the histamine H1 receptor. Originally developed, it is now off-patent and commercially available as a generic medication. It is FDA-approved to treat various allergic conditions, including allergic conjunctivitis, rhinitis, and urticaria. The commercial status of Dexchlorpheniramine Maleate is generic, with multiple manufacturers available. Key safety considerations include potential drowsiness and other central nervous system effects.","approvals":[{"date":"1981-07-14","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Dexchlorpheniramine Maleate","ecosystem":[{"indication":"Allergic conjunctivitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alcaftadine","slug":"alcaftadine","company":"Allergan"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"astemizole","slug":"astemizole","company":""}],"globalPrevalence":null},{"indication":"Dermatographic urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000},{"indication":"Itching of skin","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"allantoin","slug":"allantoin","company":""},{"name":"ammonium lactate","slug":"ammonium-lactate","company":"Ranbaxy"},{"name":"antazoline","slug":"antazoline","company":"Novartis"}],"globalPrevalence":null},{"indication":"Seasonal allergic rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"azelastine","slug":"azelastine","company":"Meda Pharms"},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":null},{"indication":"Urticaria","otherDrugs":[{"name":"alimemazine","slug":"alimemazine","company":"Allergan Herbert"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"brompheniramine","slug":"brompheniramine","company":""}],"globalPrevalence":68000000},{"indication":"Vasomotor rhinitis","otherDrugs":[{"name":"acrivastine","slug":"acrivastine","company":"Auxilium Pharms Inc"},{"name":"antazoline","slug":"antazoline","company":"Novartis"},{"name":"azatadine","slug":"azatadine","company":""},{"name":"azelastine","slug":"azelastine","company":"Meda Pharms"}],"globalPrevalence":null}],"mechanism":{"target":"Histamine H1 receptor","novelty":"Follow-on","targets":[{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"CHRM4","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M4","protein":"Muscarinic acetylcholine receptor M4"},{"gene":"CHRM1","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M1","protein":"Muscarinic acetylcholine receptor M1"},{"gene":"CHRM3","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M3","protein":"Muscarinic acetylcholine receptor M3"},{"gene":"SIGMAR1","source":"DrugCentral","target":"Sigma non-opioid intracellular receptor 1","protein":"Sigma non-opioid intracellular receptor 1"},{"gene":"SLC6A3","source":"DrugCentral","target":"Sodium-dependent dopamine transporter","protein":"Sodium-dependent dopamine transporter"},{"gene":"CHRM5","source":"DrugCentral","target":"Muscarinic acetylcholine receptor M5","protein":"Muscarinic acetylcholine receptor M5"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"}],"modality":"Small Molecule","drugClass":"dexchlorpheniramine","explanation":"","oneSentence":"","technicalDetail":"Dexchlorpheniramine Maleate is a competitive antagonist of the histamine H1 receptor, which is a G-protein coupled receptor involved in the regulation of smooth muscle contraction, vascular permeability, and other physiological processes."},"commercial":{"launchDate":"1981","_launchSource":"DrugCentral (FDA 1981-07-14, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4411","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DEXCHLORPHENIRAMINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DEXCHLORPHENIRAMINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:30:56.341655","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:20.381318+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"brompheniramine","drugSlug":"brompheniramine","fdaApproval":"1957-08-23","genericCount":13,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"chlorphenamine","drugSlug":"chlorphenamine","fdaApproval":"1950-08-15","relationship":"same-class"},{"drugName":"pheniramine","drugSlug":"pheniramine","fdaApproval":"1994-06-08","relationship":"same-class"},{"drugName":"dexbrompheniramine","drugSlug":"dexbrompheniramine","fdaApproval":"1963-10-18","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"dexchlorpheniramine","indications":{"approved":[{"name":"Allergic conjunctivitis","source":"DrugCentral","snomedId":473460002,"regulator":"FDA"},{"name":"Allergic rhinitis","source":"DrugCentral","snomedId":61582004,"regulator":"FDA"},{"name":"Dermatographic urticaria","source":"DrugCentral","snomedId":7632005,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Itching of skin","source":"DrugCentral","snomedId":418363000,"regulator":"FDA"},{"name":"Seasonal allergic rhinitis","source":"DrugCentral","snomedId":367498001,"regulator":"FDA"},{"name":"Urticaria","source":"DrugCentral","snomedId":126485001,"regulator":"FDA","usPrevalence":null,"globalPrevalence":68000000,"prevalenceMethod":"curated","prevalenceSource":"Allergy, 2020 (PMID:31494963)"},{"name":"Vasomotor rhinitis","source":"DrugCentral","snomedId":8229003,"regulator":"FDA","eligibility":"No specific eligibility criteria mentioned"}],"offLabel":[],"pipeline":[]},"drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"brompheniramine","brandName":"brompheniramine","genericName":"brompheniramine","approvalYear":"1957","relationship":"same-class"},{"drugId":"chlorphenamine","brandName":"chlorphenamine","genericName":"chlorphenamine","approvalYear":"1950","relationship":"same-class"},{"drugId":"pheniramine","brandName":"pheniramine","genericName":"pheniramine","approvalYear":"1994","relationship":"same-class"},{"drugId":"dexbrompheniramine","brandName":"dexbrompheniramine","genericName":"dexbrompheniramine","approvalYear":"1963","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06940661","phase":"PHASE2","title":"Obinutuzumab for Remission Induction in Patients With Relapsing PR3-ANCA Granulomatosis With Polyangiitis","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-12-19","conditions":["Granulomatosis With Polyangiitis"],"enrollment":33,"completionDate":"2028-07"},{"nctId":"NCT03368664","phase":"PHASE3","title":"A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT","status":"TERMINATED","sponsor":"Genzyme, a Sanofi Company","startDate":"2017-10-24","conditions":["Multiple Sclerosis"],"enrollment":16,"completionDate":"2025-09-08"},{"nctId":"NCT04702256","phase":"PHASE3","title":"Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-12-09","conditions":["Lupus Nephritis","Systemic Lupus Erythematosus (SLE)"],"enrollment":196,"completionDate":"2031-12"},{"nctId":"NCT05136976","phase":"PHASE3","title":"Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2023-06-29","conditions":["Anti-MAG Neuropathy"],"enrollment":90,"completionDate":"2028-12"},{"nctId":"NCT02433522","phase":"PHASE3","title":"Comparison Between a Long Term and a Conventional Maintenance Treatment With Rituximab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-03-31","conditions":["ANCA-associated Vasculitides"],"enrollment":97,"completionDate":"2018-08-16"},{"nctId":"NCT06766825","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-02-07","conditions":["Post COVID-19 Condition","Long COVID Syndrome","Persistent COVID-19","Persistent COVID Condition","Long COVID"],"enrollment":90,"completionDate":"2026-06-01"},{"nctId":"NCT05451784","phase":"PHASE1,PHASE2","title":"Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS","status":"RECRUITING","sponsor":"Fundacio Clinic Barcelona","startDate":"2022-07-20","conditions":["Metastatic Triple-Negative Breast Carcinoma"],"enrollment":20,"completionDate":"2027-09-30"},{"nctId":"NCT00467142","phase":"PHASE2","title":"Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Institut Bergonié","startDate":"2007-01-23","conditions":["Colorectal Cancer"],"enrollment":62,"completionDate":"2011-12"},{"nctId":"NCT03920722","phase":"PHASE3","title":"Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-24","conditions":["Microscopic Polyangiitis (MPA)"],"enrollment":8,"completionDate":"2023-09"},{"nctId":"NCT05191225","phase":"PHASE4","title":"Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study","status":"UNKNOWN","sponsor":"Laida Cuevas Palomares","startDate":"2021-09-28","conditions":["Non-Hodgkin's Lymphoma"],"enrollment":48,"completionDate":"2022-12"},{"nctId":"NCT03050866","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2017-02-21","conditions":["Circulating Tumor Cell","Metastatic Prostate Cancer"],"enrollment":140,"completionDate":"2022-08-19"},{"nctId":"NCT02583594","phase":"PHASE1","title":"A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2015-12-06","conditions":["Progressive Multiple Sclerosis"],"enrollment":24,"completionDate":"2021-03-01"},{"nctId":"NCT02523768","phase":"PHASE4","title":"Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2011-01-08","conditions":["Glomerulonephritis","IgAN"],"enrollment":117,"completionDate":"2020-02-24"},{"nctId":"NCT04384224","phase":"NA","title":"The Clinical Benefits of the Combination Use of Acupuncture and Antihistamine on Trigeminal Neuralgia","status":"UNKNOWN","sponsor":"China Medical University Hospital","startDate":"2020-07-01","conditions":["Trigeminal Neuralgia"],"enrollment":40,"completionDate":"2022-02-28"},{"nctId":"NCT01257061","phase":"PHASE3","title":"Effectiveness of Clemastine Fumarate + Dexamethasone Compared to Dexchlorpheniramine Maleate in Eczema Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2012-09-06","conditions":["Eczema"],"enrollment":310,"completionDate":"2013-08-02"},{"nctId":"NCT02675374","phase":"PHASE3","title":"Hemodynamic Instability Prevented With Polaramine® Infusion Before Extracorporeal Circulation","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-06-05","conditions":["Hemodynamic Instability","Vasoplegic Syndrome"],"enrollment":18,"completionDate":"2017-07-18"},{"nctId":"NCT03805035","phase":"NA","title":"Anti-histamines Promote Electroacupuncture Analgesia: Basic and Clinical Research","status":"COMPLETED","sponsor":"China Medical University Hospital","startDate":"2019-01-24","conditions":["Pain"],"enrollment":40,"completionDate":"2019-06-30"},{"nctId":"NCT01529242","phase":"PHASE3","title":"Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Cutaneous Rash Treatment","status":"TERMINATED","sponsor":"EMS","startDate":"2014-02","conditions":["Cutaneous Hypersensitivity"],"enrollment":17,"completionDate":"2016-10-20"},{"nctId":"NCT02441894","phase":"PHASE4","title":"Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-04","conditions":["Prostate Cancer"],"enrollment":21,"completionDate":"2016-11"},{"nctId":"NCT02735070","phase":"PHASE3","title":"Study Comparing Coristina® D to Resfenol® in the Symptomatic Treatment of Common Cold","status":"UNKNOWN","sponsor":"Brainfarma Industria Química e Farmacêutica S/A","startDate":"2016-09","conditions":["Cold"],"enrollment":366,"completionDate":"2017-03"},{"nctId":"NCT01529229","phase":"PHASE3","title":"Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment","status":"COMPLETED","sponsor":"EMS","startDate":"2013-11","conditions":["Allergic Rhinitis"],"enrollment":210,"completionDate":"2014-10"},{"nctId":"NCT01720485","phase":"PHASE3","title":"Comparison of Desloratadine Associated With Prednisolone (Tablet)Versus Dexchlorpheniramine Associated With Betamethasone (Tablet) for Adult Persistent Allergic Rhinitis Treatment","status":"UNKNOWN","sponsor":"EMS","startDate":"2013-10","conditions":["Allergic Rhinitis"],"enrollment":234,"completionDate":"2014-03"},{"nctId":"NCT01237925","phase":"PHASE3","title":"Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Gel) in the Relief of Sunburn Related Symptoms","status":"UNKNOWN","sponsor":"Mantecorp Industria Quimica e Farmaceutica Ltd.","startDate":"","conditions":["Sunburn"],"enrollment":124,"completionDate":""},{"nctId":"NCT01233934","phase":"PHASE3","title":"Comparative Study of Two Forms of Topical Dexchlorpheniramine Maleate (Cream Versus Gel) for Insect Bites","status":"UNKNOWN","sponsor":"Mantecorp Industria Quimica e Farmaceutica Ltd.","startDate":"2011-02","conditions":["Insect Bites"],"enrollment":90,"completionDate":"2011-07"},{"nctId":"NCT01085721","phase":"PHASE3","title":"Comparison Between Dexchlorpheniramine and Dexchlorpheniramine/Pseudoephedrine/Guaifenesin in Respiratory Infections","status":"UNKNOWN","sponsor":"Mantecorp Industria Quimica e Farmaceutica Ltd.","startDate":"","conditions":["Viral Infections of the Upper Respiratory Tract"],"enrollment":170,"completionDate":""},{"nctId":"NCT01085851","phase":"PHASE3","title":"Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Sunburn Related Symptoms","status":"UNKNOWN","sponsor":"Mantecorp Industria Quimica e Farmaceutica Ltd.","startDate":"","conditions":["Sunburn"],"enrollment":30,"completionDate":""},{"nctId":"NCT00995397","phase":"PHASE3","title":"Non-inferiority Clinical Trial of Dexchlorpheniramine (Cream Versus Lotion) in the Relief of Insect Bite Related Symptoms","status":"UNKNOWN","sponsor":"Mantecorp Industria Quimica e Farmaceutica Ltd.","startDate":"","conditions":["Insect Bites"],"enrollment":30,"completionDate":""},{"nctId":"NCT00846950","phase":"NA","title":"Effects of H1-Antagonist on Cognition","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2006-12","conditions":["Cognition"],"enrollment":18,"completionDate":"2007-05"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Liquid, Solution, Syrup, Tablet","formulations":[{"form":"LIQUID","route":"ORAL","productName":"RYCLORA"},{"form":"LIQUID","route":"ORAL","productName":"chlophedianol hydrochloride, dexchlorpheniramine maleate, and pseudoephedrine hydrochloride"},{"form":"LIQUID","route":"ORAL","productName":"ABATUSS DMX"},{"form":"LIQUID","route":"ORAL","productName":"DELTUSS DMX Cough Suppressant Nasal Decongestant Antihistamine GRAPE Flavor"},{"form":"LIQUID","route":"ORAL","productName":"DELTUSS DP Nasal Decongestant Antihistamine CHERRY Flavor"},{"form":"LIQUID","route":"ORAL","productName":"VANACOF"},{"form":"SOLUTION","route":"ORAL","productName":"POLMON"},{"form":"SYRUP","route":"ORAL","productName":"WesTussin DM"},{"form":"SYRUP","route":"ORAL","productName":"PRO-REDAC"},{"form":"SYRUP","route":"ORAL","productName":"Polytussin DM"},{"form":"TABLET","route":"ORAL","productName":"Dexchlorpheniramine Maleate, Phenylephrine HCl"},{"form":"TABLET, COATED","route":"ORAL","productName":"RYMED"},{"form":"TABLET, MULTILAYER","route":"ORAL","productName":"Rescon"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000147804","MMSL":"1479","NDDF":"003393","UNII":"3Q9Q0B929N","VUID":"4019712","CHEBI":"CHEBI:4464","VANDF":"4018792","INN_ID":"955","RXNORM":"22697","UMLSCUI":"C0057606","chemblId":"CHEMBL1200927","ChEMBL_ID":"CHEMBL1201353","KEGG_DRUG":"D07803","DRUGBANK_ID":"DB13679","PUBCHEM_CID":"33036","SNOMEDCT_US":"16031005","IUPHAR_LIGAND_ID":"1210","SECONDARY_CAS_RN":"2438-32-6","MESH_SUPPLEMENTAL_RECORD_UI":"C018904"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":130,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"R06AB02","allCodes":["R06AB02","R06AB52"]},"biosimilarFilings":[],"recentPublications":[{"date":"2006","pmid":"30000848","title":"Dexchlorpheniramine.","journal":""},{"date":"2025 Apr","pmid":"39740223","title":"Fixed Drug Eruption due to Chlorpheniramine: Case Report.","journal":"Contact dermatitis"},{"date":"2024 Dec 1","pmid":"39265704","title":"Comparative inhibition by oral bilastine, parenteral dexchlorpheniramine, and a new bilastine parenteral (i.v. and i.m.) formulation of histamine-induced wheal and flare response: A randomised phase I trial.","journal":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences"},{"date":"2024","pmid":"38646551","title":"Efficacy and safety of different systemic drugs in the treatment of uremic pruritus among hemodialysis patients: a network meta-analysis based on randomized clinical trials.","journal":"Frontiers in medicine"},{"date":"2024 Jan","pmid":"38239332","title":"Successful discontinuation of corticosteroids through remission induction therapy with benralizumab for chronic eosinophilic pneumonia.","journal":"Respirology case reports"}],"companionDiagnostics":[],"genericManufacturers":4,"_genericFilersChecked":true,"genericManufacturerList":["Ani Pharms","Pai Holdings Pharm","Pharmobedient","Schering"],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1981","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1981-07-14T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-07-16T00:00:00.000Z","mah":"PHARMOBEDIENT","brand_name_local":null,"application_number":"ANDA202520"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:39:20.381318+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}